BERDINI, VALERIO,CARR, MARIA GRAZIA,EARLY, THERESA RACHEL,GILL, ADRIAN LIAM,TREWARTHA, GARY,WOOLFORD, ALISON JO-ANN,WOODHEAD, ANDREW JAMES,WYATT, PAUL GRAHAM,O'BRIEN, MICHAEL ALISTAIR
申请号：
PL10175329
公开号：
PL2256106T3
申请日:
2004.07.22
申请国别(地区):
PL
年份:
2015
代理人:
摘要：
The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dcpcndcnt kinase and glycogen synthase kinase-3. In formula (0): X is a group R 1 -A-NR 4 - or a 5- or 6-membered carbocyclic or heterocyclic ring； A is a bond, SO 2 , C=O, NR g (C=O) or O(C=O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy； Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length； R 1 is hydrogen； a carbocyclic or heterocyclic group having from 3 to 12 ring members； or a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C 1-4 hydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ； R 2 is hydrogen； halogen； C 1-4 alkoxy (e.g. methoxy)； or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy)； R 3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members； and R 4 is hydrogen or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy).
